NEW YORK, March 21 - Inpharmatica said Wednesday that Genentech of South San Francisco, Calif., has acquired a three-year non-exclusive subscription to Inpharmatica's Biopendium proteomic analysis system. 

Under the terms of the multi-million dollar agreement, Inpharmatica of London, UK, will develop a customized version of Biopendium for Genentech by incorporating Genentech's proprietary genome sequence data into the platform. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.